1
NSG 552 Exam 2 Psychopharmacology
Wilkes University Actual Exam
2026/2027 with Detailed Rationales |
Complete Exam-Style Questions | Pass
Guaranteed – A+ Graded
TABLE OF CONTENTS
Section 1 | Neurobiology & Mechanisms of Action | Q1 – Q10
Section 2 | Antipsychotics & Schizophrenia Spectrum | Q11 – Q22
Section 3 | Antidepressants & Mood Stabilizers | Q23 – Q34
Section 4 | ADHD, Substance Use, Anxiety & Special Populations | Q35
– Q44
Section 5 | NGN-Style Clinical Judgment & Integrated Case Analysis |
Q45 – Q50
Instructions: Choose the single best answer. Pass: 40 in 90 minutes.
══════════════════════════════════════
SECTION 1: NEUROBIOLOGY & MECHANISMS OF ACTION Q1 –
Q10
══════════════════════════════════════
Question 1 of 50
,2
A 32-year-old patient with schizophrenia is started on a new
antipsychotic that acts as a partial agonist at the D2 receptor. The
PMHNP explains that this mechanism allows the medication to act as a
functional antagonist in mesolimbic pathways while preventing
excessive D2 blockade in the nigrostriatal pathway. Which medication
was most likely prescribed?
A. Haloperidol
B. Risperidone
C. Aripiprazole ✓ CORRECT
D. Quetiapine
Correct Answer: C
Rationale: Aripiprazole is a third-generation antipsychotic that functions
as a D2 partial agonist, stabilizing dopamine transmission by
antagonizing hyperdopaminergic mesolimbic pathways while
stimulating hypodopaminergic nigrostriatal pathways. Haloperidol is a
full D2 antagonist, which fully blocks dopamine in both pathways and
carries a much higher risk of extrapyramidal symptoms. Recognizing
partial agonism is key to understanding why aripiprazole causes minimal
movement disorders.
Question 2 of 50
A PMHNP is selecting a medication for a patient with major depressive
disorder who has a comorbid condition requiring drugs that are highly
,3
susceptible to central nervous system side effects. The PMHNP chooses
an antidepressant that is a substrate for P-glycoprotein, limiting its brain
penetration. Which pharmacokinetic concept best explains why this drug
has a lower incidence of central adverse effects?
A. Active efflux at the blood-brain barrier ✓ CORRECT
B. High first-pass hepatic metabolism
C. Rapid renal clearance from the plasma
D. Extensive protein binding in the blood
Correct Answer: A
Rationale: P-glycoprotein is an efflux transporter located on the luminal
membrane of brain capillary endothelial cells that actively pumps
substrates out of the central nervous system. High first-pass metabolism
reduces overall systemic bioavailability but does not specifically prevent
CNS penetration once the drug is in the bloodstream. This transporter
mechanism is a critical consideration when trying to minimize or
maximize central nervous system drug effects.
Question 3 of 50
A 45-year-old woman with schizophrenia presents to the clinic
complaining of galactorrhea and amenorrhea. She was recently switched
from an atypical antipsychotic to a high-potency first-generation
antipsychotic. Blockade of which specific dopamine pathway is directly
responsible for this patient's new symptoms?
, 4
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway ✓ CORRECT
Correct Answer: D
Rationale: The tuberoinfundibular pathway regulates prolactin secretion
from the anterior pituitary, and D2 blockade in this tract leads to
hyperprolactinemia, causing galactorrhea and amenorrhea. Blockade of
the nigrostriatal pathway causes extrapyramidal symptoms, while
mesolimbic blockade treats positive psychotic symptoms. Mapping
dopamine pathways to their specific clinical effects is essential for
predicting and managing antipsychotic side effects.
Question 4 of 50
A 26-year-old patient is brought to the emergency department after a
suspected benzodiazepine overdose with severe respiratory depression.
The clinician administers flumazenil, and the patient rapidly regains
consciousness. Flumazenil achieves this effect by acting as what type of
receptor ligand?
A. Full agonist
B. Competitive inverse agonist ✓ CORRECT
C. Partial agonist
D. Non-competitive antagonist
NSG 552 Exam 2 Psychopharmacology
Wilkes University Actual Exam
2026/2027 with Detailed Rationales |
Complete Exam-Style Questions | Pass
Guaranteed – A+ Graded
TABLE OF CONTENTS
Section 1 | Neurobiology & Mechanisms of Action | Q1 – Q10
Section 2 | Antipsychotics & Schizophrenia Spectrum | Q11 – Q22
Section 3 | Antidepressants & Mood Stabilizers | Q23 – Q34
Section 4 | ADHD, Substance Use, Anxiety & Special Populations | Q35
– Q44
Section 5 | NGN-Style Clinical Judgment & Integrated Case Analysis |
Q45 – Q50
Instructions: Choose the single best answer. Pass: 40 in 90 minutes.
══════════════════════════════════════
SECTION 1: NEUROBIOLOGY & MECHANISMS OF ACTION Q1 –
Q10
══════════════════════════════════════
Question 1 of 50
,2
A 32-year-old patient with schizophrenia is started on a new
antipsychotic that acts as a partial agonist at the D2 receptor. The
PMHNP explains that this mechanism allows the medication to act as a
functional antagonist in mesolimbic pathways while preventing
excessive D2 blockade in the nigrostriatal pathway. Which medication
was most likely prescribed?
A. Haloperidol
B. Risperidone
C. Aripiprazole ✓ CORRECT
D. Quetiapine
Correct Answer: C
Rationale: Aripiprazole is a third-generation antipsychotic that functions
as a D2 partial agonist, stabilizing dopamine transmission by
antagonizing hyperdopaminergic mesolimbic pathways while
stimulating hypodopaminergic nigrostriatal pathways. Haloperidol is a
full D2 antagonist, which fully blocks dopamine in both pathways and
carries a much higher risk of extrapyramidal symptoms. Recognizing
partial agonism is key to understanding why aripiprazole causes minimal
movement disorders.
Question 2 of 50
A PMHNP is selecting a medication for a patient with major depressive
disorder who has a comorbid condition requiring drugs that are highly
,3
susceptible to central nervous system side effects. The PMHNP chooses
an antidepressant that is a substrate for P-glycoprotein, limiting its brain
penetration. Which pharmacokinetic concept best explains why this drug
has a lower incidence of central adverse effects?
A. Active efflux at the blood-brain barrier ✓ CORRECT
B. High first-pass hepatic metabolism
C. Rapid renal clearance from the plasma
D. Extensive protein binding in the blood
Correct Answer: A
Rationale: P-glycoprotein is an efflux transporter located on the luminal
membrane of brain capillary endothelial cells that actively pumps
substrates out of the central nervous system. High first-pass metabolism
reduces overall systemic bioavailability but does not specifically prevent
CNS penetration once the drug is in the bloodstream. This transporter
mechanism is a critical consideration when trying to minimize or
maximize central nervous system drug effects.
Question 3 of 50
A 45-year-old woman with schizophrenia presents to the clinic
complaining of galactorrhea and amenorrhea. She was recently switched
from an atypical antipsychotic to a high-potency first-generation
antipsychotic. Blockade of which specific dopamine pathway is directly
responsible for this patient's new symptoms?
, 4
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway ✓ CORRECT
Correct Answer: D
Rationale: The tuberoinfundibular pathway regulates prolactin secretion
from the anterior pituitary, and D2 blockade in this tract leads to
hyperprolactinemia, causing galactorrhea and amenorrhea. Blockade of
the nigrostriatal pathway causes extrapyramidal symptoms, while
mesolimbic blockade treats positive psychotic symptoms. Mapping
dopamine pathways to their specific clinical effects is essential for
predicting and managing antipsychotic side effects.
Question 4 of 50
A 26-year-old patient is brought to the emergency department after a
suspected benzodiazepine overdose with severe respiratory depression.
The clinician administers flumazenil, and the patient rapidly regains
consciousness. Flumazenil achieves this effect by acting as what type of
receptor ligand?
A. Full agonist
B. Competitive inverse agonist ✓ CORRECT
C. Partial agonist
D. Non-competitive antagonist
